These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34214460)

  • 1. Sense and Sensibility.
    Schattner A
    Am J Med; 2021 Dec; 134(12):1570-1571. PubMed ID: 34214460
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
    Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
    Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.
    Yano A; Kagawa M; Takeshita H; Okada Y; Morozumi M; Kawakami S
    Int J Urol; 2017 Dec; 24(12):861-862. PubMed ID: 28895205
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bicalutamide].
    Taéron C
    Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer presenting with fever and rigors.
    Le BH; Rosenthal MA
    Intern Med J; 2005 Oct; 35(10):638. PubMed ID: 16207268
    [No Abstract]   [Full Text] [Related]  

  • 6. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
    Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
    Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Yoshida T
    Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
    [No Abstract]   [Full Text] [Related]  

  • 8. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
    Parker C; Clarke N; Logue J; Payne H; Catton C; Kynaston H; Murphy C; Morgan R; Morash C; Parulekar W; Parmar M; Savage C; Stansfeld J; Sydes M;
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
    de la Taille A
    World J Urol; 2014 Dec; 32(6):1625-6. PubMed ID: 24413818
    [No Abstract]   [Full Text] [Related]  

  • 10. Bicalutamide with radiotherapy for prostate cancer.
    Brower V
    Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
    Arai Y; Akaza H; Deguchi T; Fujisawa M; Hayashi M; Hirao Y; Kanetake H; Naito S; Namiki M; Tachibana M; Usami M; Ohashi Y
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1385-96. PubMed ID: 18491137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Unreliable survival analysis].
    Tretli S; Kvåle R; Hernes E
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429-30; author reply 430. PubMed ID: 19247405
    [No Abstract]   [Full Text] [Related]  

  • 14. [Incorrect about hormone treatment in prostatic cancer].
    Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Garnick MB
    BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
    [No Abstract]   [Full Text] [Related]  

  • 16. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
    Jia AY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Taneja SS
    J Urol; 2013 Sep; 190(3):880. PubMed ID: 23931194
    [No Abstract]   [Full Text] [Related]  

  • 18. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
    Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
    Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
    [No Abstract]   [Full Text] [Related]  

  • 19. Bicalutamide.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
    Laufer M; Sinibaldi VJ; Carducci MA; Eisenberger MA
    Urology; 1999 Oct; 54(4):745. PubMed ID: 10754148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.